--- title: "Neoadjuvant Advance or Metastatic Breast Cancer Kandela-302 | Sutter Health" description: "An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease" url: "https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Neoadjuvant Advance or Metastatic Breast Cancer Kandela-302 # Neoadjuvant Advance or Metastatic Breast Cancer Kandela-302 **Status:** Coming Soon #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492641). #### Locations - Sacramento - Palo Alto - San Mateo - Sunnyvale - Mountain View #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease ![Nitin Rohatgi, M.D., MBA](https://dyn.mktgcdn.com/p/tVS4RemP6bkC55e_mitBU2bV-F97uZqUB_hdGp4TZ6s/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Nitin Rohatgi, M.D., MBA Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017) ## Sub-Investigators [Morgan D Hines, PA-C](https://www.sutterhealth.org/research/investigators/morgan-d-hines-pa-c-2015847324) , [Natalia Colocci, M.D., Ph.D.](https://www.sutterhealth.org/research/investigators/natalia-colocci-md-phd-1049680997) , [Kim-Son Nguyen, M.D., MPA](https://www.sutterhealth.org/research/investigators/kim-son-nguyen-md-mpa-1049681024) , [Julian H McLain, M.D.](https://www.sutterhealth.org/research/investigators/julian-h-mclain-md-2064304850) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Breast Cancer A012103 OptimiCE-PCR](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-cancer-a012103-optimice-pcr-1094794503) OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Breast Cancer ER-pos/HER2-neg EA1242](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-cancer-er-pos-her2-neg-ea1242-2072227055) A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS≤25 (RxFINE-Low) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Breast NRG-BR009](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-nrg-br009-1049142000) A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Triple NegativeBreast Cancer Ascent-05](https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy **Status:** Open to Enrollment - Clinical trial ### [Advanced Breast Cancer HR+ HER2- WO45654](https://www.sutterhealth.org/research/clinical-trials/advanced-breast-cancer-hr-her2-wo45654-2044043570) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Neoadjuvant Advance or Metastatic Breast Cancer Kandela-302"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116#medicalwebpage","name":"Neoadjuvant Advance or Metastatic Breast Cancer Kandela-302","description":"An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116","inLanguage":"en-US","dateModified":"2026-10-19","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116#breadcrumblist"},"mentions":[{"@type":"Person","name":"Nitin Rohatgi, M.D., MBA","url":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116#medicaltrial","name":"Neoadjuvant Advance or Metastatic Breast Cancer Kandela-302","alternateName":"An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116","description":"An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease","identifier":"NCT07492641","code":{"@type":"MedicalCode","codeValue":"NCT07492641","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT07492641","status":"https://schema.org/NotYetRecruiting","healthCondition":[{"@type":"MedicalCondition","name":"Breast Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"},{"@type":"AdministrativeArea","name":"Palo Alto"},{"@type":"AdministrativeArea","name":"San Mateo"},{"@type":"AdministrativeArea","name":"Sunnyvale"},{"@type":"AdministrativeArea","name":"Mountain View"}]} ```